FEATURED EDITORIAL
Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the potency of cytotoxic drugs. This article shares data surrounding the ADCs currently entering clinical trials, a look at failed ADC programs, and more.
- Add Efficiency From Development To Validation With Design Of Experiments
- Dispelling 4 Common Myths Of Data Quality Governance
- Tackling Safety Issues Of Adjuvanted Vaccines
- ICH Guideline Q9(R1) On QRM, Part 2: Subjectivity & Supply Continuity
- 4 Lessons Learned Developing Cancer Immunotherapy Treatments
- Platforming Strategies To Increase Throughput With Better Standardization
- ICH Guideline Q9(R1) On QRM, Part 1: Formality & Risk-based Decisions
FEATURED APPLICATION CONTENT
-
A novel downstream processing system was developed to mitigate the downstream processing bottleneck in cell line development. Evaluate the performance of this innovative system in a mAb production process.
-
Antibody-drug conjugates (ADCs) represent a significant area of growth in the biopharmaceutical industry. Explore the capabilities of a highly scalable, productive platform to streamline ADC production processes.
-
The first line of defense against cold chain failures is the integrity of freezing containers during storage and shipping. Explore "robust by design" single-use solutions in cold chain management.
-
Manufacturers require reliable strategies to evaluate mixing performances across new equipment and consumables to ensure consistency. CFD is invaluable in determining the performance of single-use mixers during process development.
-
Learn about the basic principles that govern tangential flow filtration (TFF) along with the use of TFF capsules and cassettes in laboratory and process development applications.
-
Discover a simple, easy, and versatile method for capsule and depth filtration of small volumes that moves research from cell harvest to purification as quickly and efficiently as possible.
-
Discover a digital transformation solution that provides first of its kind data analytics for filter integrity testing. The software helps operators and supervisors reduce time lost through review processes.
-
The drug development journey is long, expensive, resource straining, and risky. Discover how to maximize the value of early phase material and match your development path to your IND milestones.
-
Explore a demonstration of strategic process control in terms of flow and pressure, by utilizing a depth filtration system, for effective depth filter processing and recovery of excess product.
-
Learn more about improving the performance of a scalable AAV process in Xcellerex™ XDR-10 and XDR-200 bioreactors using HyClone™ peak expression medium.
-
Cell line development is a complex, labor intensive, and multistep process. Learn about a platform and host cell line that minimize the risk and timeline to develop high-performing clones.
-
Discover a single-use automated filtration system designed to deliver robust process control and integrity assurance during the critical purification step. Explore its design features, processing control, and more.
FEATURED NEWS HEADLINES
- Massive Bio And NeoGenomics Announce Collaboration To Accelerate Oncology Drug Discovery And Improve Patient Care
- Invitae And Deerfield Management Partner To Create Novel Therapeutics For Rare Diseases
- Dewpoint Therapeutics Partners With Novo Nordisk To Explore The Field Of Biomolecular Condensates To Treat Insulin Resistance And Diabetes Progression
- Gyros Protein Technologies Introduces New PurePep EasyClean Services To Accelerate Development And Manufacturing Of Peptide-Based Drugs
- Lumicell Submits New Drug Application For LUMISIGHT Optical Imaging Agent To U.S. FDA For Intraoperative Breast Cancer Detection And Removal
- Altasciences Selects Proscia To Accelerate The Development Of Life-Saving Drugs
- NVIDIA Unveils Large Language Models And Generative AI Service To Advance Life Sciences R&D
- Sensei Biotherapeutics Announces Submission Of Investigational New Drug (IND) Application For SNS-101, A Conditionally Active VISTA-Blocking Antibody
- Arrowhead Receives FDA Fast Track Designation For ARO-APOC3
- Icosagen Acquires The Carterra LSA Instrument To Significantly Enhance Its Antibody Screening Capabilities In The Discovery And Development Of New Therapeutic And Diagnostic Antibodies
ARCHIVED NEWSLETTER
- 03.22.23 -- Optimize Product Life Cycles With A Collaborative Partnership Model
- 03.21.23 -- Tangential Flow Filtration For Laboratory And Process Development Applications
- 03.21.23 -- In 2023, What Trends Will Dominate Cybersecurity?
- 03.15.23 -- Antibody Variants Chromatography, And Mechanistic Modeling Trends
- 03.14.23 -- Automating Instrument Data Ingestion And Access To Accelerate Lab Productivity